MED24

Across TCGA pan-cancer cohorts, MED24 Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated MED24 data layer compared with 28 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in colon adenocarcinoma (COAD), where higher MED24 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated MED24 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

COAD, LAML, and UCEC are the cancer types where MED24 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
COAD	OS	Median	IV	0.082	0.659	<.001	15	view →
LAML	DFS	Median	All	0.140	0.582	.020	12	view →
UCEC	DFS	Median	All	0.920	0.614	.010	10	view →
LIHC	OS	Median	II,III,IV	0.221	0.718	.001	9	view →
CHOL	OS	Median	All	0.155	0.725	.029	3	view →
BLCA	DFS	Median	IV	0.186	0.481	.043	3	view →
SKCM	DFS	Median	All	0.408	0.616	.034	2	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

MED24–COAD (OS)

Open the COAD breakdown →